Skip to main content

Articles

336 result(s) for 'ctla 4' within BMC Cancer

Page 2 of 7

  1. Nivolumab is an immune checkpoint inhibitor specific to the programmed death 1 (PD-1) receptor. Nivolumab has shown clinical responses in many malignancies. Although immune-related adverse events (irAEs) assoc...

    Authors: Koji Yoshino, Takayuki Nakayama, Ayumu Ito, Eiichi Sato and Shigehisa Kitano
    Citation: BMC Cancer 2019 19:1019
    Content type: Case report Published on:

  2. Immune checkpoint inhibitors-induced myocarditis presents unique clinical challenges. Here, we assessed post-marketing safety of cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), programmed cell death-1 (PD-1...

    Authors: Rulan Ma, Quanziang Wang, Deyu Meng, Kang Li and Yong Zhang
    Citation: BMC Cancer 2021 21:38
    Content type: Research article Published on:

  3. Cancer immunotherapy via immune-checkpoint inhibition (ICI) by antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and cell death protein 1 (PD-...

    Authors: J. Boegeholz, C. S. Brueggen, C. Pauli, F. Dimitriou, E. Haralambieva, R. Dummer, M. G. Manz and C. C. Widmer
    Citation: BMC Cancer 2020 20:300
    Content type: Research article Published on:

  5. Programmed cell death protein-1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have remarkable clinical efficacy in the treatment of non-small cell lung cancer (NSCLC); however, the breakdown of ...

    Authors: Xiaoying Sun, Raheleh Roudi, Ting Dai, Shangya Chen, Bin Fan, Hongjin Li, Yaqiong Zhou, Min Zhou, Bo Zhu, Chengqian Yin, Bin Li and Xin Li
    Citation: BMC Cancer 2019 19:558
    Content type: Research article Published on:

  6. The predictive role of blood-based tumor mutation burden (bTMB) for selecting advanced nonsmall cell lung cancer (NSCLC) patients who might benefit from immune checkpoint inhibitors (ICIs) is still under debat...

    Authors: He Ba, Lei Liu, Qiang Peng, Jie Chen and Yao-dong Zhu
    Citation: BMC Cancer 2021 21:1220
    Content type: Research Published on:

  7. Secreted phosphoprotein 1 (SPP1) plays a vital role in tumor progression of multiple cancer types However, it still awaits further exploration whether SPP1 is a bystander or an actual player in the modulation ...

    Authors: Wen Gao, Dongli Liu, Haiyan Sun, Zhuyan Shao, Peipei Shi, Tingting Li, Sheng Yin and Tao Zhu
    Citation: BMC Cancer 2022 22:1367
    Content type: Research Published on:

  8. Follicular thyroid carcinoma (FTC) is the second most common cancer of the thyroid and easily develops into distant metastasis. PD-L1 is known to be associated with the carcinogenesis and progression of thyroi...

    Authors: Jianguang Lin, Yanru Qiu, Xueqin Zheng, Yijun Dai and Tianwen Xu
    Citation: BMC Cancer 2022 22:756
    Content type: Research Published on:

  9. Numerous studies have revealed that gamma delta (γδ) T cell infiltration plays a crucial regulatory role in hepatocellular carcinoma (HCC) development. Nonetheless, a comprehensive analysis of γδ T cell infilt...

    Authors: Jingrui Wang, Sunbin Ling, Jie Ni and Yafeng Wan
    Citation: BMC Cancer 2022 22:638
    Content type: Research Published on:

  10. Signaling through VEGF/VEGFR induces cancer angiogenesis and affects immune cells. An increasing number of studies have recently focused on combining anti-VEGF/VEGFR agents and immune checkpoint inhibitors (IC...

    Authors: Liting Xue, Xingyuan Gao, Haoyu Zhang, Jianxing Tang, Qian Wang, Feng Li, Xinxin Li, Xiaohong Yu, Zhihong Lu, Yue Huang, Renhong Tang and Wenqing Yang
    Citation: BMC Cancer 2021 21:1134
    Content type: Research Published on:

  11. Lung adenocarcinoma (LUAD) is an extraordinarily malignant tumor, with rapidly increasing morbidity and poor prognosis. Immunotherapy has emerged as a hopeful therapeutic modality for lung adenocarcinoma. Furt...

    Authors: Qianhe Ren, Qifan Li, Chenye Shao, Pengpeng Zhang, Zhuangzhuang Hu, Jun Li, Wei Wang and Yue Yu
    Citation: BMC Cancer 2023 23:897
    Content type: Research Published on:

  12. The likelihood of a tumor recurrence in patients with T3-4N0–1 non-small cell lung cancer following multimodality treatment remains substantial, mainly due distant metastases. As pathological complete response...

    Authors: Chris Dickhoff, Suresh Senan, Famke L. Schneiders, Joris Veltman, Sayed Hashemi, Johannes M. A. Daniels, Marieke Fransen, David J. Heineman, Teodora Radonic, Peter M. van de Ven, Imke H. Bartelink, Lilian J. Meijboom, Juan J. Garcia-Vallejo, Daniela E. Oprea-Lager, Tanja D. de Gruijl and Idris Bahce
    Citation: BMC Cancer 2020 20:764
    Content type: Study protocol Published on:

  13. Transporter associated with antigen processing 1 (TAP1) is a molecule involved in processing and presentation of major histocompatibility complex class I restricted antigens, including tumor-associated antigen...

    Authors: Zewei Tu, Kuangxun Li, Qiankun Ji, Yuyang Huang, Shigang Lv, Jingying Li, Lei Wu, Kai Huang and Xingen Zhu
    Citation: BMC Cancer 2023 23:133
    Content type: Research Published on:

  14. The median time from primary melanoma diagnosis to brain metastasis was 3.2 years. The median overall survival duration from the time of initial brain metastasis was 12.8 months. Following a diagnosis of brain me...

    Authors: Elham Vosoughi, Jee Min Lee, James R. Miller, Mehdi Nosrati, David R. Minor, Roy Abendroth, John W. Lee, Brian T. Andrews, Lewis Z. Leng, Max Wu, Stanley P. Leong, Mohammed Kashani-Sabet and Kevin B. Kim
    Citation: BMC Cancer 2018 18:490
    Content type: Research article Published on:

  15. The PD-1/PD-L1 axis plays a paramount role in the immune escape of tumor cells by negative regulation of T-cell functions. The aim of the present study was to characterize the PD-L1 expression pattern and its ...

    Authors: Chan Kim, Eun Kyung Kim, Hun Jung, Hong Jae Chon, Jung Woo Han, Kyoo-Ho Shin, Hyuk Hu, Kyung Sik Kim, Young Deuk Choi, Sunghoon Kim, Young Han Lee, Jin-Suck Suh, Joong Bae Ahn, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha…
    Citation: BMC Cancer 2016 16:434
    Content type: Research article Published on:

  17. A 71-year-old gentleman with pancreatic adenocarcinoma underwent the Whipple procedure in September 2014. The patient received 8 cycles of adjuvant chemotherapy with gemcitabineand achieved a complete responsein ...

    Authors: Yuan Liu, Zhi Liu, Xuejun Zeng, Chunmei Bai, Lin Chen, Songbai Lin and Xinlun Tian
    Citation: BMC Cancer 2019 19:1193
    Content type: Case report Published on:

  19. Most immune-related adverse event (irAE) patterns and treatment guidelines are based on western clinical data. We evaluated the incidence and patterns of irAEs in patients treated with immune-checkpoint inhibi...

    Authors: Nuttapong Ngamphaiboon, Suthinee Ithimakin, Teerada Siripoon, Nattaya Sintawichai and Virote Sriuranpong
    Citation: BMC Cancer 2021 21:1275
    Content type: Research Published on:

  20. With the application of immune checkpoint inhibitors (ICIs) in cancer treatment, more and more attention has been paid to checkpoint inhibitor-related pneumonitis (CIP), which requires a better understanding o...

    Authors: Li Pang, Mei Xie, Xidong Ma, Aiben Huang, Jialin Song, Jie Yao, Hui Deng, Duchao Zhang, Xuelei Zang, Fangping Ren, Jie Gao, Chongchong Wu, Yuanyong Wang, Xin Zhang, Xinyu Bao, Lei Pan…
    Citation: BMC Cancer 2023 23:203
    Content type: Research Published on:

  21. Less than half of unselected metastatic cancer patients benefit from the immune checkpoint inhibitor (ICI) therapy. Systemic cancer-related inflammation may influence the efficacy of ICIs and thus, systemic in...

    Authors: Satu Tiainen, Veera Nurmela, Tuomas Selander, Patrik Turunen, Sanna Pasonen-Seppänen, Tiia Kettunen, Outi Kuittinen, Päivi Auvinen and Aino Rönkä
    Citation: BMC Cancer 2023 23:1186
    Content type: Research Published on:

  22. Treatment outcomes of advanced non-small cell lung cancer (NSCLC) have substantially improved with immune checkpoint inhibitors (ICI), although only approximately 19% of patients respond to immunotherapy alone...

    Authors: Andrew F. Nyein, Shahla Bari, Stephanie Hogue, Yayi Zhao, Bradley Maller, Sybil Sha, Maria F. Gomez, Dana E. Rollison and Lary A. Robinson
    Citation: BMC Cancer 2022 22:101
    Content type: Research Published on:

  23. Immune checkpoint inhibitors (ICIs) has shown remarkable benefit in the treatment of a range of cancer types, although it may initiate immune related adverse events (irAEs) in patients. Some studies have shown...

    Authors: Xiaoyun Zhang, Shuo Xu, Jiaqi Wang, Yalei Lv, Na Wang, Ruixue Lai, Ziyue Sha, Qun Zhao and Zhanjun Guo
    Citation: BMC Cancer 2022 22:1136
    Content type: Research Published on:

  24. FoxP3+ Regulatory T cells (Tregs) and indoleamine-2,3-dioxygenase (IDO) participate in the formation of an immunosuppressive tumor microenvironment (TME) in malignant cutaneous melanoma (CM). Recent studies ha...

    Authors: Satu Salmi, Anton Lin, Benjamin Hirschovits-Gerz, Mari Valkonen, Niina Aaltonen, Reijo Sironen, Hanna Siiskonen and Sanna Pasonen-Seppänen
    Citation: BMC Cancer 2021 21:641
    Content type: Research article Published on:

  25. The association between immune-related adverse events (irAEs) and survival outcomes in patients with advanced melanoma receiving therapy with immune checkpoint inhibitors (ICIs) has not been well established, ...

    Authors: Chiao-En Wu, Chan-Keng Yang, Meng-Ting Peng, Pei-Wei Huang, Ching-Fu Chang, Kun-Yun Yeh, Chun-Bing Chen, Chih-Liang Wang, Chao-Wei Hsu, I-Wen Chen, Cheng-Tao Lin, Shir-Hwa Ueng, Gigin Lin, Yu-Fen Lin, Chi-Yuan Cheng and John Wen-Cheng Chang
    Citation: BMC Cancer 2020 20:1018
    Content type: Research article Published on:

  26. This study aimed to assess the effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing treatment with immune checkpoint inhibitors (ICIs).

    Authors: Hyunho Kim, Ji Eun Lee, Sook Hee Hong, Myung Ah. Lee, Jin Hyoung Kang and In-Ho Kim
    Citation: BMC Cancer 2019 19:1100
    Content type: Research article Published on:

  27. Nonerythrocytic spectrin beta 1 (SPTBN1) is an important cytoskeletal protein that involves in normal cell growth and development via regulating TGFβ/Smad signaling pathway, and is aberrantly expressed in vari...

    Authors: Wenting Tang, Qiong Shao, Zhanwen He, Xu Zhang, Xiaojuan Li and Ruohao Wu
    Citation: BMC Cancer 2023 23:303
    Content type: Research Published on:

  28. Other iatrogenic immunodeficiency-associated (OIIA) T- and natural killer (NK)-cell lymphoproliferative disorders (TNK-LPDs) are rare in patients with rheumatoid arthritis (RA).

    Authors: Shoichi Kimura, Yumi Oshiro, Hiromi Iwasaki, Masanori Kadowaki, Masao Ogata, Tsutomu Daa, Toshifumi Sakata, Shigeto Kawauchi, Ziyao Wang, Yasushi Takamatsu and Morishige Takeshita
    Citation: BMC Cancer 2022 22:1342
    Content type: Research article Published on:

  29. Esophagogastric adenocarcinoma (EGA) currently represents a main cause of cancer related death. Despite an intensified treatment for locally advanced or metastatic EGA with a doublet chemotherapy consisting of...

    Authors: Joseph Tintelnot, Eray Goekkurt, Mascha Binder, Peter Thuss-Patience, Sylvie Lorenzen, Jorge Riera Knorrenschild, Albrecht Kretzschmar, Thomas Ettrich, Udo Lindig, Lutz Jacobasch, Daniel Pink, Salah-Eddin Al-Batran, Axel Hinke, Susanna Hegewisch-Becker, Sven Nilsson, Carsten Bokemeyer…
    Citation: BMC Cancer 2020 20:503
    Content type: Study protocol Published on:

  30. Ipilimumab has shown long-term overall survival (OS) in patients with advanced melanoma in clinical trials, but robust real-world evidence is lacking. We present long-term outcomes from the IMAGE study (NCT015...

    Authors: Stéphane Dalle, Laurent Mortier, Pippa Corrie, Michal Lotem, Ruth Board, Ana María Arance, Frank Meiss, Patrick Terheyden, Ralf Gutzmer, Brian Buysse, Kelly Oh, Jane Brokaw, T. Kim Le, Susan D. Mathias, Julie Scotto, Jennifer Lord-Bessen…
    Citation: BMC Cancer 2021 21:642
    Content type: Research article Published on:

  31. Accumulating evidence has revealed that the gut microbiota influences the effectiveness of immune checkpoint inhibitors (ICIs) in cancer patients. As a part of the human microbiome, Helicobacter pylori (H. pylori...

    Authors: Hebin Che, Qi Xiong, Jinxia Ma, Shixue Chen, Huan Wu, Hongli Xu and Baicun Hou
    Citation: BMC Cancer 2022 22:904
    Content type: Research Published on:

  32. Pancreatic cancer (PC) is a highly lethal and aggressive disease with its incidence and mortality quite discouraging. A robust prognostic signature and novel biomarkers are urgently needed for accurate stratif...

    Authors: Chengcheng Wang, Yuan Chen, Yin Xinpeng, Ruiyuan Xu, Jianlu Song, Rexiati Ruze, Qiang Xu and Yupei Zhao
    Citation: BMC Cancer 2022 22:879
    Content type: Research Published on:

  33. While immunotherapy combined with chemotherapy (Chemo-IO) is generally recognized for providing superior outcomes compared to monotherapy (mono-IO), it is associated with a higher incidence of treatment-relate...

    Authors: Sangwon Shin, Jimin Moon, Chiyoon Oum, Seulki Kim, Soo Ick Cho, Yoojoo Lim, Chan-Young Ock and Seunghwan Shin
    Citation: BMC Cancer 2024 24:152
    Content type: Research Published on:

  34. The combination of nivolumab, a programmed death-1 (PD-1) targeted monoclonal antibody, with the cytotoxic T-lymphocyte antigen-4 (CTLA-4) targeted antibody, ipilimumab, represents a new ... with nivolumab increa...

    Authors: Hannah L. Buckley, Fiona J. Collinson, Gemma Ainsworth, Heather Poad, Louise Flanagan, Eszter Katona, Helen C. Howard, Geraldine Murden, Rosamonde E. Banks, Joanne Brown, Galina Velikova, Tom Waddell, Kate Fife, Paul D. Nathan, James Larkin, Thomas Powles…
    Citation: BMC Cancer 2019 19:1102
    Content type: Study protocol Published on:

  36. Trials investigating neoadjuvant treatment with immune checkpoint inhibitors (ICI) in patients with melanoma have shown high clinical and pathologic response rates. Treatment with talimogene laherparepvec (T-V...

    Authors: Maartje W. Rohaan, Emma H. A. Stahlie, Viola Franke, Lisanne P. Zijlker, Sofie Wilgenhof, Vincent van der Noort, Alexander C. J. van Akkooi and John B. A. G. Haanen
    Citation: BMC Cancer 2022 22:851
    Content type: Study protocol Published on:

  37. Bladder cancer (BLCA) typically has a poor prognosis due to high relapse and metastasis rates. A growing body of evidence indicates that N6-methyladenosine (m6A) and long non-coding RNAs (lncRNAs) play crucial...

    Authors: Tianming Ma, Xiaonan Wang, Lingfeng Meng, Xiaodong Liu, Jiawen Wang, Wei Zhang, Zijian Tian and Yaoguang Zhang
    Citation: BMC Cancer 2021 21:1256
    Content type: Research Published on:

  38. The association between specific genetic mutations and immunotherapy benefits has been widely known, while such studies in pan-cancer are still limited. SPEN, mainly involved in X chromosome inactivation (XCI)...

    Authors: Ya-Dong Li, Hao Huang, Zheng-Ju Ren, Ye Yuan, Hao Wu and Chuan Liu
    Citation: BMC Cancer 2023 23:793
    Content type: Research Published on:

  39. The optimal first-line immunotherapy regimen for advanced non-squamous non-small cell lung cancer (NS-NSCLC) patients with programmed cell death ligand 1 (PD-L1) expression ≥ 50% remains unclear. Our aim is to...

    Authors: Wei Chen, Jiayi Chen, Lin Zhang, Sheng Cheng and Junxian Yu
    Citation: BMC Cancer 2023 23:791
    Content type: Research Published on:

  40. Colorectal cancer (CRC) is one of the most common malignancies worldwide. Immunotherapy targeting the programmed death protein 1(PD-1) and its ligand (PD-L1), is a promising treatment option for many cancers, ...

    Authors: Yuying Dong, Mingming Zheng, Xiaoxuan Wang, Chenyue Yu, Tiantian Qin and Xuning Shen
    Citation: BMC Cancer 2023 23:1097
    Content type: Research Published on:

  41. Immunotherapy is a crucial therapeutic approach in oncology. However, most patients with head and neck squamous cell carcinoma (HNSCC) do not derive benefit from immunotherapy. Vascular endothelial growth fact...

    Authors: Chao Zhu, Liqun Gu, Zelong Liu, Jiang Li, Mianfeng Yao and Changyun Fang
    Citation: BMC Cancer 2021 21:836
    Content type: Research Published on:

  42. The mortality rate of hepatocellular carcinoma (HCC) remains high worldwide despite surgery and chemotherapy. Immunotherapy is a promising treatment for the rapidly expanding HCC spectrum. Therefore, it is nec...

    Authors: Weike Gao, Luan Li, Xinyin Han, Siyao Liu, Chengzhen Li, Guanying Yu, Lei Zhang, Dongsheng Zhang, Caiyun Liu, Erhong Meng, Shuai Hong, Dongliang Wang, Peiming Guo and Guangjun Shi
    Citation: BMC Cancer 2021 21:331
    Content type: Research article Published on:

  43. Recent evidences had shown that loss in phosphatase and tensin homolog deleted on chromosome 10 (PTEN) was associated with immunotherapy resistance, which may be attributed to the non-T-cell-inflamed tumor mic...

    Authors: Ziying Lin, Lixia Huang, Shao Li Li, Jincui Gu, Xiaoxian Cui and Yanbin Zhou
    Citation: BMC Cancer 2021 21:429
    Content type: Research article Published on:

  44. Tumor debulking surgery followed by adjuvant chemotherapy or radiotherapy is a standard treatment for many solid malignancies. Although this approach can be effective, it often has limited success against recu...

    Authors: Andrea Khong, Amanda L Cleaver, Muhammad Fahmi Alatas, Ben C Wylie, Theresa Connor, Scott A Fisher, Steve Broomfield, Willem J Lesterhuis, Andrew J Currie, Richard A Lake and Bruce W Robinson
    Citation: BMC Cancer 2014 14:969
    Content type: Research article Published on:

  45. Hypofractionated palliative radiotherapy for metastatic lung cancer patients is frequently used in order to ease pain, to increase bone stability, to treat local mass effects, or to prolong progression-free su...

    Authors: Farastuk Bozorgmehr, Adriane Hommertgen, Johannes Krisam, Felix Lasitschka, Jonas Kuon, Martin Maenz, Peter E. Huber, Laila König, Meinhard Kieser, Juergen Debus, Michael Thomas and Stefan Rieken
    Citation: BMC Cancer 2019 19:1074
    Content type: Study protocol Published on:

  46. Infiltrating immune and stromal cells are vital components of the bladder cancer (BC) microenvironment, which can significantly affect BC progression and outcome. However, the contribution of each subset of tu...

    Authors: Ye Zhang, De-hua Ou, Dong-wu Zhuang, Ze-feng Zheng and Ming-en Lin
    Citation: BMC Cancer 2020 20:265
    Content type: Research article Published on:

  47. The gut microbiome is implicated as a marker of response to  immune checkpoint inhibitors (ICI) based on preclinical mouse models and preliminary observations in limited patient series. Furthermore, early stud...

    Authors: Nicola A. Thompson, Grant D. Stewart, Sarah J. Welsh, Gary J. Doherty, Matthew J. Robinson, B. Anne Neville, Kevin Vervier, Simon R. Harris, David J. Adams, Katy Dalchau, David Bruce, Nikolaos Demiris, Trevor D. Lawley and Pippa G. Corrie
    Citation: BMC Cancer 2022 22:99
    Content type: Study protocol Published on:

  48. Owing to non-responsiveness of a high number of patients to the common melanoma therapies, seeking novel approaches seem as an unmet requirement. Chimeric antigen receptor (CAR) T cells were initially employed...

    Authors: Maryam Bahmanyar, Mohammad Kazem Vakil, Ghaidaa Raheem Lateef Al-Awsi, Seyed Amin Kouhpayeh, Yaser Mansoori, Behnam Mansoori, Ali Moravej, Abdulbaset Mazarzaei and Abdolmajid Ghasemian
    Citation: BMC Cancer 2022 22:1220
    Content type: Research Published on:

  50. Immune checkpoint inhibitors (ICI) treatment in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) offers new therapeutic venues. We have previously developed a predictive survival model ...

    Authors: Majd Issa, Brett G. Klamer, Nikol Mladkova, Georgios I. Laliotis, Vidhya Karivedu, Priyanka Bhateja, Chase Byington, Khaled Dibs, Xueliang Pan, Arnab Chakravarti, John Grecula, Sachin R. Jhawar, Darrion Mitchell, Sujith Baliga, Matthew Old, Ricardo L. Carrau…
    Citation: BMC Cancer 2022 22:767
    Content type: Research Published on:

Featured videos

View featured videos from across the BMC-series journals

Submit manuscript

Follow

BMC Cancer

ISSN: 1471-2407

Contact us